Roadmap for tuberculosis elimination in Latin American and Caribbean countries: A strategic alliance

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1282-1287

  Rendon, Adrian ^a,b   Fuentes, Zhenia ^b,c   Torres Duque, Carlos A ^d,e   Del Granado, Mirtha ^f   Victoria, Jorge ^f   Duarte, Raquel ^g   Migliori, Giovanni Battista ^f  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Latin American Thoracic Association (ALAT)   (United States)

^c Hospital General Dr Jose Ignacio Baldo   (Venezuela)

^d Tuberculosis Dept   (United States)

^e FUNDACIÓN NEUMOLÓGICA COLOMBIANA   (Colombia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g General Dirct of Health   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CARBAPENEM; DELAMANID; LINEZOLID; RIFAMPICIN;

CARIBBEAN; COMORBIDITY; HEALTH CARE POLICY; HEALTH PROMOTION; HUMAN; INCIDENCE; MORTALITY RATE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOUTH AND CENTRAL AMERICA; TUBERCULOSIS; TUBERCULOSIS CONTROL; DISEASE ERADICATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; WORLD HEALTH ORGANIZATION;

CARIBBEAN REGION; DISEASE ERADICATION; HEALTH POLICY; HUMANS; LATIN AMERICA; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84994213389     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01549-2016     Document Type: Review

References (18)

1. World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. Geneva, World Health Organization, 2015.
2. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
3. Pan American Health Organization. Strategic Plan of the Pan American Health Organization 2014-2019. 52nd Directing Council of PAHO, 65th session of the WHO Regional Committee for the Americas; 2013 Sep 30 to Oct 4. www.paho.org/hq/index.php?gid=14004&option=com-docman&task=doc-view Date last accessed: August 2, 2016.
4. Pan American Health Organization. Plan de Acción para la Prevención y el Control de la Tuberculosis. 54°Consejo Directivo, 67a. Sesión del Comité Regional de la OMS para las Américas. Washington, D.C., EUA. September 28th to October 2nd, 2015. http://www.paho.org/hq/index.php?option=com-docman&task=doc-view&gid=31244&Itemid=270&lang=es Date last accessed: August 2, 2016.
5. World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Document WHO/HTM/TB 2015.19. Geneva, World Health Organization, 2015.
6. United Nations. Millenium Declaration. General Assembly, Fifty-fifth session of the General Assembly of the United Nations; 2000 Sep 5 to 2001 Sep 11; New York (NY), US. New York, UN, 2000 (Document A/RES/55/2). www.un.org/millennium/declaration/ares552e.pdf Date last accessed: August 2, 2016.
7. Pan American Health Organization. Regional Office for the Americas. Tuberculosis in the Americas. Regional Report 2014. Epidemiology, Control, and Financing. www.paho.org/hq/index.php?option=com-topics&view=readall&cid=5626&Itemid=40776&lang=en Date last accessed: August 2, 2016.
8. Pan American Health Organization. Tuberculosis. Regional Plan for Tuberculosis Control, 2006-2015. www.stoptb.org/assets/documents/global/plan/tb-reg-plan-2006-15AMRO.pdf Date last accessed: August 2, 2016.
9. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
10. Pareek M, Greenaway C, Noori T, et al. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med 2016; 14: 48.
11. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
12. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 1235-1243.
13. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 1758-1766.
14. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and Safety of imipenem clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug resistant and extensively drug resistant tuberculosis. Clin Infect Dis 2016; 62: 1188-1190.
15. Arbex MA, Bonini EH, Kawakame Pirolla G, et al. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis in Brazil. Rev Port Pneumol 2016 [in press DOI: 10.1016/j.rppnen.2016.06.006].
16. Arbex MA, Ribeiro de Siqueira H, D'Ambrosio L, et al. The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases. J Bras Pneumol 2015; 41: 554-559.
17. Rendon A, Centis R, D'Ambrosio L, et al. WHO strategies for the management of drug-resistant tuberculosis. Arch Bronconeumol 2016 [in press].
18. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Eur Respir J 2016 [in press DOI: 10.1183/13993003.01249.2016].